Bobby_2006
Well-known member
The 2026 pipeline is genuinely significant - oral semaglutide approval plus the cagrilintide combination data plus continued biosimilar development changes the access picture substantially. The pivotal year framing holds up when you look at the regulatory and patent timeline together.